Evaluation of the effectiveness of a joint general practitioner-pharmacist intervention on the implementation of benzodiazepine deprescribing in older adults (BESTOPH-MG trial): protocol for a cluster-randomized controlled trial.
benzodiazepines
collaborative practice
deprescribing
implementation
primary care
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
05
2023
accepted:
15
08
2023
medline:
15
9
2023
pubmed:
15
9
2023
entrez:
15
9
2023
Statut:
epublish
Résumé
Deprescribing benzodiazepines and related drugs (BZDR) is a challenge due to a lack of time on physicians' part, a lack of involvement of other health professionals, and the need for adapted tools. This study is based on primary care collaboration, by evaluating the effectiveness of a joint intervention between general practitioners and community pharmacists on the implementation of BZDR deprescribing in older adults. This is a cluster randomized controlled trial in which each cluster will be formed by a physician-pharmacist pair. Within a cluster allocated to the intervention, the pharmacist will be trained in motivational interviewing (MI), and will offer the patient 3 interviews after inclusion by the physician. They will base their intervention on validated deprescribing guidelines. The pharmacist will receive methodological support during the first interviews. Interprofessional collaboration will be encouraged by writing reports for the physician after each interview. The following implementation outcomes will be evaluated: acceptability/adoption, appropriateness, cost, and fidelity. They will be measured by means of sociological interviews, observations, logbooks, and cost-utility analysis. Focus groups with physicians and pharmacists will be carried out to identify levers and barriers experienced in this collaboration. Observations will be conducted with pharmacists to assess their approach of the MIs. Effectiveness outcomes will be based on medication (discontinuation or reduction of BZDR) and clinical outcomes (such as quality of life, insomnia or anxiety), assessed by health insurance databases and validated questionnaires. This study will determine whether collaboration in primary care between physicians and pharmacists, as well as training and coaching of pharmacists in motivational interviewing, allows the implementation of BZDR deprescribing in the older adults.This study will provide an understanding of the processes used to implement deprescribing guidelines, and the contribution of collaborative practice in implementing BZDR discontinuation. The cluster methodology will allow to assess the experience of the relationship between the different primary care actors, and the related obstacles and levers.The results obtained will make it possible to produce guidelines on the involvement of community pharmacists in the management of substance abuse in older adults, or even to legislate new missions or care pathways. ClinicalTrials.gov, identifier, NCT05765656.
Sections du résumé
Background
UNASSIGNED
Deprescribing benzodiazepines and related drugs (BZDR) is a challenge due to a lack of time on physicians' part, a lack of involvement of other health professionals, and the need for adapted tools. This study is based on primary care collaboration, by evaluating the effectiveness of a joint intervention between general practitioners and community pharmacists on the implementation of BZDR deprescribing in older adults.
Methods
UNASSIGNED
This is a cluster randomized controlled trial in which each cluster will be formed by a physician-pharmacist pair. Within a cluster allocated to the intervention, the pharmacist will be trained in motivational interviewing (MI), and will offer the patient 3 interviews after inclusion by the physician. They will base their intervention on validated deprescribing guidelines. The pharmacist will receive methodological support during the first interviews. Interprofessional collaboration will be encouraged by writing reports for the physician after each interview. The following implementation outcomes will be evaluated: acceptability/adoption, appropriateness, cost, and fidelity. They will be measured by means of sociological interviews, observations, logbooks, and cost-utility analysis. Focus groups with physicians and pharmacists will be carried out to identify levers and barriers experienced in this collaboration. Observations will be conducted with pharmacists to assess their approach of the MIs. Effectiveness outcomes will be based on medication (discontinuation or reduction of BZDR) and clinical outcomes (such as quality of life, insomnia or anxiety), assessed by health insurance databases and validated questionnaires.
Discussion
UNASSIGNED
This study will determine whether collaboration in primary care between physicians and pharmacists, as well as training and coaching of pharmacists in motivational interviewing, allows the implementation of BZDR deprescribing in the older adults.This study will provide an understanding of the processes used to implement deprescribing guidelines, and the contribution of collaborative practice in implementing BZDR discontinuation. The cluster methodology will allow to assess the experience of the relationship between the different primary care actors, and the related obstacles and levers.The results obtained will make it possible to produce guidelines on the involvement of community pharmacists in the management of substance abuse in older adults, or even to legislate new missions or care pathways.
Clinical trial registration
UNASSIGNED
ClinicalTrials.gov, identifier, NCT05765656.
Identifiants
pubmed: 37711743
doi: 10.3389/fmed.2023.1228883
pmc: PMC10498124
doi:
Banques de données
ClinicalTrials.gov
['NCT05765656']
Types de publication
Journal Article
Langues
eng
Pagination
1228883Investigateurs
Laurent Flet
(L)
Erwan Corbineau
(E)
Alexandra Gallin-Castagne
(A)
Maxime Lebeaupin
(M)
Leïla Moret
(L)
Émilie Guegan
(É)
Pascal Artarit
(P)
Valéry-Pierre Riche
(VP)
Informations de copyright
Copyright © 2023 Huon, Nizet, Caillet, Lecompte, Victorri-Vigneau, Fournier and the BESTOPH-MG consortium.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Drugs Aging. 2022 Sep;39(9):739-748
pubmed: 35896779
Syst Rev. 2022 Aug 13;11(1):169
pubmed: 35964148
J Clin Psychopharmacol. 2000 Feb;20(1):99
pubmed: 10653216
J Pers Med. 2022 Apr 15;12(4):
pubmed: 35455759
BMC Med Res Methodol. 2003 Dec 22;3:28
pubmed: 14690550
Curr Opin Psychiatry. 2005 May;18(3):249-55
pubmed: 16639148
Trials. 2014 Apr 23;15:139
pubmed: 24755011
Patient Educ Couns. 2004 May;53(2):147-55
pubmed: 15140454
Int J Environ Res Public Health. 2023 Feb 17;20(4):
pubmed: 36834238
Drug Saf. 2021 Jan;44(1):53-62
pubmed: 33125663
Implement Sci. 2022 Jul 8;17(1):41
pubmed: 35804428
BMC Geriatr. 2023 Jul 12;23(1):428
pubmed: 37438697
BMJ. 2005 Nov 19;331(7526):1169
pubmed: 16284208
Ann Pharm Fr. 2012 Jan;70(1):46-52
pubmed: 22341008
BMJ Open. 2019 Jan 30;9(1):e022046
pubmed: 30705235
Curr Psychiatry Rep. 2016 Oct;18(10):89
pubmed: 27549604
Pharmacol Res Perspect. 2019 Apr 25;7(3):e00476
pubmed: 31049205
J Am Geriatr Soc. 1999 Jan;47(1):30-9
pubmed: 9920227
Patient Educ Couns. 2022 Mar;105(3):615-624
pubmed: 34183219
Br J Clin Pharmacol. 2021 Mar;87(3):722-724
pubmed: 32851681
J Pain. 2017 Mar;18(3):308-318
pubmed: 27908840
Contemp Clin Trials. 2005 Apr;26(2):260-7
pubmed: 15837446
Presse Med. 2018 Oct;47(10):878-881
pubmed: 30454579
JAMA. 2018 Nov 13;320(18):1889-1898
pubmed: 30422193
Fam Pract. 1994 Dec;11(4):358-62
pubmed: 7895961
Int J Epidemiol. 2020 Jun 1;49(3):979-995
pubmed: 32087011
JAMA Intern Med. 2014 Jun;174(6):890-8
pubmed: 24733354
BMJ. 2014 Sep 09;349:g5205
pubmed: 25208536
JAMA Intern Med. 2015 May;175(5):827-34
pubmed: 25798731
Ther Adv Drug Saf. 2022 Aug 23;13:20420986221118143
pubmed: 36052398
Can Fam Physician. 2018 Aug;64(8):584-587
pubmed: 30108077
Pharmacoeconomics. 2006;24(7):683-94
pubmed: 16802844
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Eur J Intern Med. 2017 Mar;38:3-11
pubmed: 28063660
Res Social Adm Pharm. 2018 Jan;14(1):18-25
pubmed: 28214150
PLoS One. 2016 Apr 19;11(4):e0151066
pubmed: 27093289
JAMA. 2013 Jun 12;309(22):2331-2
pubmed: 23700165
J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1172-81
pubmed: 17921433
Psychol Med. 2003 Oct;33(7):1223-37
pubmed: 14580077
Health Expect. 2022 Feb;25(1):355-365
pubmed: 34862703
Drugs Aging. 2022 Oct;39(10):773-794
pubmed: 36194370
EClinicalMedicine. 2020 Oct 16;28:100596
pubmed: 33294812
Addict Behav. 2004 Aug;29(6):1059-65
pubmed: 15236807
Cochrane Database Syst Rev. 2011 May 11;(5):CD008063
pubmed: 21563163
N Engl J Med. 2016 Aug 4;375(5):454-63
pubmed: 27518663